非典型抗精神病藥物在抗精神病藥中占有重要位置,。然而，很少有研究對抗精神病藥在精神?？?a href="http://hnhlg.com/sell/list-153.html" target="_blank">醫(yī)院中-長時間住院患者中的應(yīng)用進(jìn)展進(jìn)行評估,。目前，一項發(fā)表在最新一期Int J Psychiat Clin雜志上的研究"The use of antipsychotics in a medium–long stay psychiatric hospital from 1998 to 2010"著重分析了自1998年至2010年,，抗精神病藥在精神?？漆t(yī)院中-長時間住院患者中的應(yīng)用進(jìn)展。
該項研究對1998年-2010年所有在精神?？漆t(yī)院住院231天的患者的抗精神病藥物消費數(shù)據(jù)和費用進(jìn)行評估,；從住院數(shù)據(jù)庫中獲取患者住院天數(shù)。最佳日劑量（DDD）由世界健康組織（WHO）界定,。此外,，研究亦采用新近的專家共識推薦對抗精神病藥的使用率進(jìn)行評估。采用個體DDD或所有抗精神病藥的總等效劑量/年住院天數(shù),，計算抗精神病藥的使用情況,。
結(jié)果發(fā)現(xiàn)自1998年至2010年，抗精神病藥的使用率增加至135%,；采用專家共識推薦進(jìn)行計算,，則抗精神病藥的使用率增加至108%,。自1998年以來,，抗精神病藥的費用花費增加6倍。這種費用的增長與非典型抗精神病藥的使用增加有關(guān),。
因此,，13年來,，抗精神病藥的使用率至少增加2倍。這種增長與非典型抗精神病藥的使用增加有關(guān),，非典型藥物的使用導(dǎo)致總抗精神病藥物費用花費增加6倍,。然而，這種處方類型的改變是否可獲得明顯的臨床效益尚不明確,。（生物谷Bioon.com）
doi:10.3109/13651501.2011.633172
PMC:
PMID:
The use of antipsychotics in a medium–long stay psychiatric hospital from 1998 to 2010
Unax Lertxundi1, Saioa Domingo Echaburu2 & Rafael Hernandez Palacios3
Objective. Atypical agents have emerged as the dominant choice among antipsychotics. Data about development of antipsychotic use in medium–long stay psychiatric hospitals is lacking. Material and methods. Antipsychotic drug consumption data and cost was obtained from 1998 to 2010 for all inpatients of a 231-bed psychiatric hospital. Number of hospital stays was obtained from the hospital admission unit. Daily defined dose (DDD) values were those assigned by the WHO. Antipsychotic use was also measured using recently available consensus-based recommendations. Antipsychotic use was then calculated as the sum of individual DDD or total equivalent doses of all antipsychotics divided by the annual stay number. Results. Antipsychotic use increased 135% from 1998 to 2010 when measured in DDDs or 108% when measured with the consensus-based recommendations. Antipsychotic expenditure has risen six-fold since 1998. This augmentation is due to the increase of use of atypical antipsychotics. Conclusion. In conclusion, antipsychotic use has at least doubled in the last 13 years. This growth, attributable to an increase in atypical drug use, has contributed to a six-fold increase in the total antipsychotic expenditure. Whether this prescription pattern has translated into palpable clinical benefits remains unclear.
